Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 54 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Vasopressor Clear all

Conditions: Sepsis, Septic Shock
Interventions: drotrecogin alfa (activated); Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 2
States / cities: Camden, New Jersey • Akron, Ohio

Conditions: Psoriasis, Plaque Psoriasis
Interventions: Halobetasol Propionate Lotion 0.05%, Placebo; Drug
Lead sponsor: Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: San Diego, California • Fridley, Minnesota • Austin, Texas

Conditions: Septic Shock, Weight, Body
Interventions: Not listed
Lead sponsor: Methodist Health System; Other
Eligibility: 18 Years and older
Enrollment: 945 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Healthy
Interventions: Epinephrine/phenylephrine; Drug
Lead sponsor: New York Presbyterian Brooklyn Methodist Hospital; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Liver Failure
Interventions: Vasopressin, Normal saline placebo; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 80 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Septic Shock
Interventions: selepressin, placebo; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 868 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 17
States / cities: Colorado Springs, Colorado • Idaho Falls, Idaho • Chicago, Illinois + 13 more

Conditions: Vasoplegic Syndrome
Interventions: Hydroxocobalamin, Cardiopulmonary Bypass, Placebos; Drug · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Ischemia, Vasopressor
Interventions: Injection of botulinum toxin A; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Alopecia, Radiodermatitis
Interventions: Norepinephrine; Drug
Lead sponsor: ProCertus BioPharm, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Distributive Shock
Interventions: Angiotensin II, Placebo; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Blood Pressure
Interventions: Routine Blood Pressure Management, Tight Blood Pressure Management, Phenylephrine, Norepinephrine; Procedure · Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 45 Years and older
Enrollment: 6,254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 4
States / cities: Omaha, Nebraska • Cleveland, Ohio

Conditions: Septic Shock
Interventions: Early Vasopressors, Early Fluids; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 1,563 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 50
States / cities: Tucson, Arizona • Fresno, California • Los Angeles, California + 36 more

Conditions: Shock, Septic
Interventions: 25% Albumin, Placebo; Drug
Lead sponsor: Alexander Flannery, 859-323-4011; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Septic Shock
Interventions: Levo-Carnitine, placebo; Drug
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 14
States / cities: Birmingham, Alabama • Sacramento, California • Wilmington, Delaware + 9 more

Conditions: Septic Shock, Vasodilatory Shock
Interventions: Angiotensin II; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Head and Neck Cancer, Patients Requiring a Free Flap Surgery
Interventions: FloTrac; Device
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Hypotension, Critical Illness
Interventions: Midodrine, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Cirrhosis, Liver, Liver Fibrosis, Ascites Hepatic
Interventions: PHIN-214 Subcutaneous injection; Drug
Lead sponsor: PharmaIN; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 9
States / cities: Chandler, Arizona • Coronado, California • Marrero, Louisiana + 5 more

Conditions: Vasodilatory Hypotension During or After Cardiac Surgery
Interventions: Angiotensin II; Drug
Lead sponsor: University of Maryland St. Joseph Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Towson, Maryland

Conditions: Shock
Interventions: Fluids; Other
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1,639 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Sepsis, Low Blood Pressure
Interventions: Midodrine, Standard of Care; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 5
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Mankato, Minnesota + 2 more

Conditions: Hypotension and Shock, Pulmonary Hypertension of the Newborn (PPHN), Hypoxemic Respiratory Failure
Interventions: Dopamine administration, Norepinephrine; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: Up to 28 Days
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Methamphetamine Use Disorder
Interventions: Methamphetamine, Methylphenidate, Placebo oral capsule, Duloxetine; Drug
Lead sponsor: Craig Rush; Other
Eligibility: 18 Years to 55 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: Lexington, Kentucky

Conditions: Septic Shock
Interventions: Angiotensin II, Vasopressin; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Search by objective public record fields.

Hemodynamic and Perfusion Response to Drotrecogin Alfa (Activated) in Patients With Septic Shock

A Study to Determine the Efficacy and Safety of Halobetasol Propionate Lotion 0.05% in Subjects With Plaque Psoriasis

Time to Lose the Weight? Comparison of Weight-based and Non-weight-based Vasopressors for Septic Shock

A Randomized, Double-Blind, Trial Comparing Epinephrine Versus Phenylephrine as a Vasoconstrictor in Regional Anesthesia for Upper Extremity Surgery

Study to Evaluate if the Drug Vasopressin Protects the Kidneys for Patients Undergoing Liver Transplant

Selepressin Evaluation Programme for Sepsis-Induced Shock - Adaptive Clinical Trial

Vitamin B12a Vasoplegic Syndrome

Treatment of Vasopressor-induced Ischemia With Botulinum Toxin A

Exploratory Study of Norepinephrine to Prevent Alopecia in Head and Neck Cancer Patients Treated With Radiotherapy

Angiotensin II for Distributive Shock

The GUARDIAN Trial - Vasopressor Sub-Study

Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis

Effect of Albumin Administration on Vasopressor Duration in Resolving Septic Shock

Rapid Administration of Carnitine in sEpsis

Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock

A Prospective Study Evaluating the Use of Intraoperative Stroke Volume Variation Via the FloTrac Device to Guide Fluid and Vasopressor Management in Head and Neck Free Flaps

Midodrine for the Treatment of Refractory Hypotension

Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics

ANG-First Trial (Angiotensin II as First-Line Vasopressor Therapy in Cardiac Surgery)

Variation in Fluids Administered in Shock

MID-STEP (MIDodrine for Sepsis Treatment and Early vasoPressor Weaning) Trial

Dopamine vs. Norepinephrine for Hypotension in Neonates With Pulmonary Hypertension (DONE)

Behavioral Effects of Drugs (Inpatient): 40 [Methamphetamine, Methylphenidate, Duloxetine]

Angiotensin II vs. Vasopressin in Septic Shock